A Home-Based Study to Enhance Activity in Breast Cancer Survivors
There is a well-documented association between physical activity & risk for breast cancer development and recurrence. It is known that exercise interventions have been effective at increasing physical activity levels in breast cancer survivors. Knowing that breast cancer survivors are less active than non-cancer patients, a less active lifestyle places them at risk of obesity and poor overall health, which in turn also increases risk of cancer and cancer recurrence. Not all the reasons for the risk reduction are clear, however it is known that hormones and other inflammatory markers play a role.
This study has three goals:
- To investigate the feasibility of a home intervention designed to reduce sedentary behavior.
- Describe the effects of the intervention on levels of sedentary behavior, physical activity, and symptoms.
- Assess cost of the intervention.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
There is a well-documented association between physical activity and risk for breast cancer development and recurrence. Exercise training interventions have been effective at increasing physical activity levels in breast cancer survivors, however they require 1) a large degree of patient initiative to achieve positive health outcomes associated with sustained behavioral change and 2) facilities and oversight that may be prohibitive in a clinical setting. Although most activity-based research to date has focused on increasing levels of moderate to vigorous physical activity (MVPA) for breast cancer survivors, large epidemiological studies suggest that breast cancer survivors are also more sedentary when compared to non-cancer controls. A recent meta-analysis of controlled intervention trials designed to promote physical activity among sedentary cancer survivors found that none of the trials within the scope of the review succeeded in achieving 75% or better adherence to prescribed exercise guidelines, leading the authors to question whether shifting the target of intervention from MVPA to reductions in sedentary time might be a more realistic goal. Recent research suggests that interventions designed to reduce sedentary time in breast cancer survivors have the potential to yield clinically meaningful health benefits, especially for individuals at higher risk for sedentary behaviors, however the optimal method of intervention is not clear.
Aim 1: Feasibility of the intervention Assess the feasibility of an intervention designed to reduce sedentary behavior in breast cancer survivors. The behavioral intervention will involve the review of a 7-day baseline snapshot of sedentary behavior and physical activity patterns, combined with tailored activity prompts described over the following 6 weeks.
Aim 2: Effects of the intervention Aim 2a: Describe a preliminary range of effect sizes of the intervention on levels of sedentary behavior, physical activity and symptoms of cancer survivorship (e.g. cancer related fatigue).
Aim 2b: Evaluate the relationship between change in sedentary behavior and change in cancer-relevant outcomes, such as fatigue and biomarkers of cancer recurrence (e.g. IGF-1, Leptin), following the reduced sedentary time intervention.
Aim 3: Assessment of intervention components Aim 3a: Quantitatively assess overall cost of the intervention and its individual components, dose delivered and dose received by intervention participants Aim 3b: Quantitatively describe intervention participants' perspectives on the impact of the individual intervention components, including which components appeared most useful for reducing sedentary time.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Massachusetts
-
Springfield, Massachusetts, Spojené státy, 01109
- Baystate Medical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Stage I-III breast cancer survivors 20-80 who have completed primary treatment (surgery, radiation and/or chemotherapy) greater than 6 months but less than 5 years ago. Patients may be on adjuvant hormonal therapy
- BMI > 25 (overweight or class I/II obese)
- Not meeting current guidelines for regular exercise as defined by less than 150 minutes a week of moderate to vigorous physical activity
- No gain or loss of >10% body weight over the prior 6 months.
Exclusion Criteria:
- Known diabetes
- Known coronary artery disease
- Pregnancy
- Any injury that would limit mobility or require use of assisted mobility devices
- Weight gain or loss of >10% body weight over the prior 6 months
- Greater than 150 minutes a week of moderate to vigorous physical activity
- Inability to provide informed consent
- Non-english speaking
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Jiný: Reduced Sedentary Time Intervention
Reduced Sedentary Time Intervention (RSTI)
|
Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant.
For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time.
This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sedentary Time
Časové okno: 8 weeks
|
Change in minutes/day of sedentary time as recorded by ActivPal in all 25 participants pre and post intervention.
|
8 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Activity Level
Časové okno: 8 weeks
|
Change in Activity level as recorded by Actigraph monitor in all 25 participants
|
8 weeks
|
|
Glucose
Časové okno: 8 weeks
|
Change in fasting glucose ( mmol/L)in all 25 participants
|
8 weeks
|
|
Insulin
Časové okno: 8 weeks
|
Change in insulin (pmol/L) in all 25 participants
|
8 weeks
|
|
Total cholesterol
Časové okno: 8 weeks
|
Change in total cholesterol (mmol) in all 25 participants
|
8 weeks
|
|
High density lipoprotien cholesterol
Časové okno: 8 weeks
|
Change in high density lipoprotein cholesterol (mmol) in all 25 participants
|
8 weeks
|
|
Triglyceride
Časové okno: 8 weeks
|
Change in triglycerides (mmol) in all 25 participants
|
8 weeks
|
|
Body Mass Index
Časové okno: 8 weeks
|
Change in Body Mass Index (kg/m2) in all 25 participants
|
8 weeks
|
|
Waist Circumference
Časové okno: 8 weeks
|
Change in waist circumference in cm in all 25 participants
|
8 weeks
|
|
Systolic Blood pressure
Časové okno: 8 weeks
|
Change in systolic blood pressure measured in mmHg in all 25 participants
|
8 weeks
|
|
Diastolic Blood pressure
Časové okno: 8 weeks
|
Change in diastolic blood pressure measured in mmHg in all 25 participants
|
8 weeks
|
|
Cancer-related fatigue measured by change in PROMIS short form 8a in all 25 participants
Časové okno: 8 weeks
|
8 weeks
|
|
|
Cancer-related fatigue as measured by change in Visual Analog scale in all 25 participants
Časové okno: 8 weeks
|
8 weeks
|
|
|
Sedentary behavior self -efficacy
Časové okno: 8 weeks
|
Change in Sedentary Behavior Self-Efficacy Scale (modified from BARSE) in all 25 participants
|
8 weeks
|
|
Change in EORTC-QLQ-C30 scores in all 25 participants
Časové okno: 8 weeks
|
8 weeks
|
|
|
Assessment of Intervention
Časové okno: 8 weeks
|
Change in Assessment of Intervention questions on a scale of 1-5 in all 25 participants
|
8 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Grace Makari-Judson, MD, Baystate Medical Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 776553-5
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Rakovina prsu
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital a další spolupracovníciDokončenoPrůvodce klinickou aplikací Conebeam Breast CTČína
-
Gangnam Severance HospitalNáborHER2 Enriched Subtype Cancer Breast, Herzuma, PAM50 StudyKorejská republika
-
BioNTech SESeventh Framework ProgrammeDokončenoRakovina prsu (Triple Negative Breast Cancer (TNBC))Švédsko, Německo
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Zatím nenabírámeAnatomický karcinom prsu stadia II AJCC v8 | Anatomický karcinom prsu stadia III AJCC v8 | Rané stadium karcinomu prsu | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Emory UniversityNational Cancer Institute (NCI)StaženoPrognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v mozku | Metastatický karcinom prsu | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktivní, ne náborAnatomický karcinom prsu stadia IV AJCC v8 | Prognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v kosti | Metastatický maligní novotvar v lymfatických uzlinách | Metastatický maligní novotvar v játrech | Metastatický karcinom prsu | Metastatický maligní novotvar v plicích | Metastatický... a další podmínkySpojené státy, Kanada, Saudská arábie, Korejská republika